NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$26.52 -0.06 (-0.23 %)
(As of 12/13/2018 03:37 PM ET)
Previous Close$26.58
Today's Range$26.10 - $26.80
52-Week Range$13.66 - $33.44
Volume9,892 shs
Average Volume803,132 shs
Market Capitalization$1.42 billion
P/E Ratio-75.40
Dividend YieldN/A
Beta0.87
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VNDA
Previous Symbol
CUSIP92165910
Phone202-734-3400

Debt

Debt-to-Equity RatioN/A
Current Ratio6.03
Quick Ratio6.01

Price-To-Earnings

Trailing P/E Ratio-75.40
Forward P/E Ratio126.29
P/E Growth3.7

Sales & Book Value

Annual Sales$165.08 million
Price / Sales8.43
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.92 per share
Price / Book9.08

Profitability

EPS (Most Recent Fiscal Year)($0.35)
Net Income$-15,560,000.00
Net Margins7.06%
Return on Equity5.88%
Return on Assets4.57%

Miscellaneous

Employees273
Outstanding Shares52,450,000
Market Cap$1.42 billion
OptionableOptionable

Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.18. The biopharmaceutical company had revenue of $49.13 million for the quarter, compared to analysts' expectations of $49.44 million. Vanda Pharmaceuticals had a net margin of 7.06% and a return on equity of 5.88%. The company's quarterly revenue was up 18.9% on a year-over-year basis. During the same period last year, the company earned ($0.03) earnings per share. View Vanda Pharmaceuticals' Earnings History.

When is Vanda Pharmaceuticals' next earnings date?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for Vanda Pharmaceuticals.

What guidance has Vanda Pharmaceuticals issued on next quarter's earnings?

Vanda Pharmaceuticals updated its FY 2018 earnings guidance on Wednesday, November, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $180-200 million, compared to the consensus revenue estimate of $192.44 million.

What price target have analysts set for VNDA?

9 brokers have issued 12 month target prices for Vanda Pharmaceuticals' stock. Their forecasts range from $26.00 to $52.00. On average, they expect Vanda Pharmaceuticals' stock price to reach $40.1429 in the next twelve months. This suggests a possible upside of 51.4% from the stock's current price. View Analyst Price Targets for Vanda Pharmaceuticals.

What is the consensus analysts' recommendation for Vanda Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vanda Pharmaceuticals.

What are Wall Street analysts saying about Vanda Pharmaceuticals stock?

Here are some recent quotes from research analysts about Vanda Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, ". We are upgrading and increasing our 12-month PT to $43 from $26. Vanda announced that tradipitant met the primary endpoint in its P2 study in patients with idiopathic and diabetic gastroparesis. Based on our recent KOL due diligence, we are impressed with the effect size magnitude, which points to a clinically meaningful increase in nausea-free days, indicating a clear improvement in patient QoL. Importantly, subgroup analysis of pts experiencing both nausea and vomiting at baseline (n=101) shows that tradi’ met the primary endpoint of change in nausea score (p=0.00002) as well as the number of nausea-free days (p=0.0003), a tough putt" result." (12/4/2018)
  • 2. According to Zacks Investment Research, "Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. " (11/17/2018)
  • 3. Stifel Nicolaus analysts commented, "We reiterate our Buy rating and $30 target price. All relevant disclosures and certifications appear on pages 3 – 5 of this report. Stifel does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.Investment Thesis We believe Vanda’s current valuation is an attractive entry point for investors, given its accelerating base business and relatively de-risked, late-stage pipeline that we believe is under-appreciated." (10/31/2018)

Has Vanda Pharmaceuticals been receiving favorable news coverage?

Press coverage about VNDA stock has been trending somewhat positive on Thursday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vanda Pharmaceuticals earned a news impact score of 2.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days.

Who are some of Vanda Pharmaceuticals' key competitors?

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the folowing people:
  • Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 58)
  • Mr. James Patrick Kelly, Exec. VP, CFO, Treasurer & Sec. (Age 52)
  • Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 49)
  • Mr. Gian Piero Reverberi, Sr. VP & Chief Commercial Officer (Age 52)
  • Mr. Timothy Williams, Sr. VP, Gen. Counsel & Sec.

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (16.89%), Vanguard Group Inc. (7.57%), Macquarie Group Ltd. (5.11%), Renaissance Technologies LLC (3.91%), Glenmede Trust Co. NA (3.37%) and FMR LLC (2.13%). Company insiders that own Vanda Pharmaceuticals stock include Gunther Birznieks, James Patrick Kelly, Mihael Hristos Polymeropoulos and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.

Which institutional investors are selling Vanda Pharmaceuticals stock?

VNDA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Stonepine Capital Management LLC, Stonepine Capital Management LLC, FMR LLC, First Manhattan Co., Alambic Investment Management L.P., Man Group plc and Prudential Financial Inc.. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gunther Birznieks, James Patrick Kelly and Mihael Hristos Polymeropoulos. View Insider Buying and Selling for Vanda Pharmaceuticals.

Which institutional investors are buying Vanda Pharmaceuticals stock?

VNDA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Glenmede Trust Co. NA, Vanguard Group Inc., Wells Fargo & Company MN, Bank of New York Mellon Corp, Renaissance Technologies LLC, Dimensional Fund Advisors LP and Acadian Asset Management LLC. View Insider Buying and Selling for Vanda Pharmaceuticals.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $26.52.

How big of a company is Vanda Pharmaceuticals?

Vanda Pharmaceuticals has a market capitalization of $1.42 billion and generates $165.08 million in revenue each year. The biopharmaceutical company earns $-15,560,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Vanda Pharmaceuticals employs 273 workers across the globe.

What is Vanda Pharmaceuticals' official website?

The official website for Vanda Pharmaceuticals is http://www.vandapharmaceuticals.com.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE N.W. SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]


MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  404 (Vote Outperform)
Underperform Votes:  236 (Vote Underperform)
Total Votes:  640
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe VNDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel